Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

N/ANot Yet RecruitingNCT06599411

Assistance Publique - Hôpitaux de Paris700 enrolled

Overview

Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable. The discovery of prognosis factors will help to precisely guide the treatment regimen and its intensification based on individual markers. The identification of new therapeutic targets is essential to develop new innovative treatments for inflammatory skin diseases. The main objective is to identify new cellular or molecular prognostic factors associated with treatment response at 1 year in inflammatory skin diseases. The secondary objectives are a better understanding of the pathophysiology of chronic inflammatory skin diseases, the identification of new cellular, molecular and microbiological prognostic factors associated with the clinical state after 10 years of evolution and the identification of prognostic markers of drug toxicity.

Study Type

OBSERVATIONAL

Enrollment

700

Conditions

Atopic Dermatitis Psoriasis Hidradenitis Suppurativa Lichen Planus Cutaneous Lupus Dermatomyositis

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Patients: * Age\>18 years * Informed consent signed by the patient * Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis * Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification \[1\], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction). Healthy controls : * Age\>18 years * Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants * Informed consent signed by the patient * Absence of known cutaneous or systemic inflammatory disease. Exclusion Criteria: * Under guardianship or curatorship * Pregnant or breastfeeding woman * Lack of affiliation with a social security system * Systemic treatment in progress or received less than 3 months ago.

Outcomes

Primary Outcomes

Therapeutic response

It is defined as complete or partial remission on the Investigator/Physician Global Assessment (IGA/PGA) scale.

Time frame: At 1 year

Secondary Outcomes

Expression of markers of blood and skin immunological signaling pathways

Mainly Th1, Th2, Th9, Th17, Th22 and Treg

Time frame: At inclusion

Expression of markers of blood and skin immunological signaling pathways

Mainly Th1, Th2, Th9, Th17, Th22 and Treg

Time frame: At 4 months

Expression of markers of blood and skin immunological signaling pathways

Mainly Th1, Th2, Th9, Th17, Th22 and Treg

Time frame: At 1 year

Expression of markers of blood T cell populations and skin transcriptomics

Time frame: At inclusion

Expression of markers of blood T cell populations and skin transcriptomics

Time frame: At 4 months

Expression of markers of blood T cell populations and skin transcriptomics

Time frame: At 1 year

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At inclusion

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At 4 months

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At 1 year

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At 2 years

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At 3 years

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At 4 years

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At 5 years

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At 6 years

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At 7 years

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At 8 years

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At 9 years

Therapeutic response

Based on markers of blood T cell populations and skin transcriptomics

Time frame: At 10 years

Microbiota markers

Identification of cluster specific to the pathology, identification of an over-representation of one or more microbiological species. For patients and controls

Time frame: At inclusion

Microbiota markers

Identification of cluster specific to the pathology, identification of an over-representation of one or more microbiological species. For patients only

Time frame: At 1 year